Quantum Biopharma (NASDAQ:QNTM) Stock Price Down 23.5% – What’s Next?

Quantum Biopharma Ltd. (NASDAQ:QNTM)’s share price traded down 23.5% on Monday . The stock traded as low as $5.25 and last traded at $5.25. 694,342 shares were traded during trading, an increase of 68% from the average session volume of 412,351 shares. The stock had previously closed at $6.86.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Weiss Ratings cut shares of Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Wall Street Zen cut shares of Quantum Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Quantum Biopharma Trading Down 23.5%

The business’s 50 day moving average is $4.94 and its two-hundred day moving average is $5.77. The company has a market cap of $20.06 million, a PE ratio of -0.64 and a beta of 0.35.

Quantum Biopharma (NASDAQ:QNTM) last released its earnings results on Thursday, March 26th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.49).

Institutional Trading of Quantum Biopharma

Several hedge funds have recently bought and sold shares of QNTM. Jane Street Group LLC purchased a new stake in Quantum Biopharma in the 4th quarter worth $80,000. Virtu Financial LLC purchased a new stake in Quantum Biopharma in the 4th quarter worth $76,000. Finally, Platform Technology Partners purchased a new stake in Quantum Biopharma in the 1st quarter worth $199,000. Hedge funds and other institutional investors own 1.24% of the company’s stock.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.